NHS Carbon Reduction Plan 2027: a harder test for suppliers

The NHS's own carbon footprint fell 14% in the five years to 2024/25, and most of that reduction came from buildings, fleet and medicines rather than from the goods and services the health service buys in. That imbalance starts to close on 1 April 2027, when NHS England's Carbon Reduction Plan requirements move from a narrow slice of supplier emissions to the full value chain: every scope 1, 2 and relevant scope 3 category, calculated globally, signed off at board level and published. Any pharmaceutical or medtech company holding, or bidding for, an NHS contract worth £5 million a year or more will need to report emissions it has rarely had to quantify before. So will every supplier bidding into a new NHS framework, open framework or dynamic market, regardless of contract value.

Most current NHS suppliers already comply with an earlier, narrower version of the Carbon Reduction Plan, in place since April 2023 under Procurement Policy Note 06/21. What arrives in 2027 asks for something on a different scale.

What changes in 2027

Today's standard requires a Carbon Reduction Plan covering scope 1 and 2 emissions plus five defined scope 3 categories: upstream and downstream transport, waste, business travel and employee commuting. A net zero commitment for UK operations by 2050, board or director approval, and publication on the supplier's website complete the requirement.

From 1 April 2027, that plan must instead cover all relevant scope 3 emissions, calculated globally, in line with the full GHG Protocol standard rather than five defined categories. The net zero commitment extends to the whole organisation, not just UK operations, by 2050 at the latest, though NHS England encourages 2045 to match its own Carbon Footprint Plus target for indirect emissions. Assessment stays pass or fail rather than scored, through two standardised questions alongside the emissions data, and the reporting period covered must be no more than 18 months old when a tender is published.

The scope of who this applies to also widens. Contracts worth £5 million a year or more (including VAT) sit inside the enhanced requirement, and so, regardless of value, does every new framework, open framework and dynamic purchasing system the NHS runs.

From five categories to the full value chain

The five scope 3 categories in today's Carbon Reduction Plan, transport, waste, travel and commuting, are largely operational: they measure how a company moves people and goods, not what it makes or sells. The GHG Protocol's full scope 3 standard adds categories that sit much closer to a product itself: purchased goods and services, capital goods, upstream leased assets, processing of sold products, use of sold products, and end-of-life treatment of sold products.

For a company supplying consumables, equipment or medicines into the NHS, those last two categories, use and disposal, are usually where the bulk of a product's lifetime emissions sit, not in how staff commute to work. Moving from the current five categories to the full standard changes which companies can produce a credible answer.

Why medtech and pharma feel this first

The NHS's own five-year progress is a story of direct control: emissions from medicines administration (inhaler propellants and anaesthetic gases) fell 33%, zero-emission vehicles went from one in a hundred NHS fleet vehicles to one in ten, and clinical waste emissions dropped 32%. Each of those levers sits inside the health service's own estate and procurement choices.

Scope 3 categories like purchased goods and services, and the use and end-of-life of sold products, sit inside manufacturing and product design decisions the NHS does not control. For a medtech company, that means device energy consumption across years of clinical use and the disposal of single-use consumables both count, categories that have so far been discussed mostly at the level of industry position and circularity strategy rather than measured and published as hard numbers. MedTech Europe's own sustainability programme, still centred on circularity principles and a November 2025 policy paper rather than sector-wide quantified targets, illustrates how early that measurement work generally is. For pharmaceutical companies, active ingredient manufacture and distribution frequently sit overseas, so a genuinely global scope 1 to 3 figure reaches into supply chains that have rarely needed UK-style carbon accounting at all.

The 2028 follow-on

A further requirement, due in 2028, asks suppliers for cradle-to-grave lifecycle emissions data on the individual products they sell into the NHS supply chain, rather than company-wide figures. That means life cycle assessment work, product by product, rather than one organisational Carbon Reduction Plan covering an entire supplier relationship.

Companies that start that life cycle assessment work ahead of a formal requirement will reach 2028 with usable data rather than trying to collate data against a deadline. Given how far the 2027 rules already stretch beyond current practice for most suppliers, treating 2028 as a separate problem is unlikely to leave enough runway.

Where this leaves suppliers

The NHS can point to a 14% five-year cut and a named set of figures behind it because the changes it made were within its own control.  The 2027 and 2028 rules test whether pharmaceutical and medtech suppliers can do the same for emissions that sit inside their own manufacturing, product design and service delivery, whether that is a device's energy use in the field or the fleet and travel behind an outsourced clinical contract.

For companies preparing NHS bids ahead of April 2027, the practical question is less whether to comply than whether existing supplier and product data can be assembled in time. CHASE's market intelligence work with pharmaceutical and medtech clients increasingly tracks NHS policy changes like this one alongside the commercial case, because a strong bid built on data that does not exist yet is not a strong bid. Get in touch with our team to find out more about how we can help.

CHASE works with pharmaceutical and medtech companies on NHS market access and commercial strategy. Our insights and market access team tracks NHS policy changes like this one for clients preparing bids and commercial plans.